In the past week, IMAB stock has gone down by 0.00%, with a monthly gain of 19.18% and a quarterly plunge of -21.99%. The volatility ratio for the week is 6.66%, and the volatility levels for the last 30 days are 9.82% for I-Mab ADR The simple moving average for the past 20 days is 9.14% for IMAB’s stock, with a -18.13% simple moving average for the past 200 days.
Is It Worth Investing in I-Mab ADR (NASDAQ: IMAB) Right Now?
The 36-month beta value for IMAB is at 1.09. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMAB is 76.81M, and currently, shorts hold a 1.18% of that float. The average trading volume for IMAB on January 24, 2025 was 450.20K shares.
IMAB) stock’s latest price update
The stock price of I-Mab ADR (NASDAQ: IMAB) has surged by 3.77 when compared to previous closing price of 1.06, prnewswire.com reported 2025-01-08 that Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the Company has been informed that Wei Fu, the Chairman of the Board, intends to purchase up to $2,000,000 of the Company’s ADSs in open market transactions.
Analysts’ Opinion of IMAB
Many brokerage firms have already submitted their reports for IMAB stocks, with Siebert Williams Shank repeating the rating for IMAB by listing it as a “Buy.” The predicted price for IMAB in the upcoming period, according to Siebert Williams Shank is $96 based on the research report published on December 09, 2021 of the previous year 2021.
Needham gave a rating of “Buy” to IMAB, setting the target price at $75 in the report published on March 15th of the previous year.
IMAB Trading at 9.83% from the 50-Day Moving Average
After a stumble in the market that brought IMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.12% of loss for the given period.
Volatility was left at 9.82%, however, over the last 30 days, the volatility rate increased by 6.66%, as shares surge +12.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.45% lower at present.
During the last 5 trading sessions, IMAB fell by -0.45%, which changed the moving average for the period of 200-days by -39.50% in comparison to the 20-day moving average, which settled at $1.0077. In addition, I-Mab ADR saw 29.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMAB starting from KANNAN RAJ, who proposed sale 50,000 shares at the price of $1.39 back on Jul 26 ’24. After this action, KANNAN RAJ now owns shares of I-Mab ADR, valued at $69,500 using the latest closing price.
Stock Fundamentals for IMAB
Current profitability levels for the company are sitting at:
- -100.18 for the present operating margin
- 1.0 for the gross margin
The net margin for I-Mab ADR stands at -80.35. The total capital return value is set at -1.81. Equity return is now at value -39.60, with -30.80 for asset returns.
Currently, EBITDA for the company is -1.21 billion with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 134.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.50.
Conclusion
In conclusion, I-Mab ADR (IMAB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
